Elismetrep
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Elismetrep
- Molecular weight
- 542.54
- Structure (SMILES)
- O=C(O)c1ccc(S(=O)(=O)N(Cc2ccc(OC(F)(F)F)cc2)c2ncc3ccccc3c2C2CC2)cc1
- 4 4 cyclopropylisoquinolin 3 yl 4 trifluoromethoxy benzyl sulfamoyl benzoic acid
- 4-((4-CYCLOPROPYLISOQUINOLIN-3-YL) (4-(TRIFLUOROMETHOXY) BENZYL) SULFAMOYL) BENZOIC ACID
- elismetrep
- Elismetrep
- Elismetrep (K-304) 10 mg
- Elismetrep (K-304) 2 mg
- Elismetrep (K-304) 20 mg
- Elismetrep (K-304) 5 mg
- elismetrep [INN]
- ELISMETREP [USAN]
- elismetrep inn
- elismetrep usan
- mt 8554
- Mt-8554
- MT-8554
- MT-8554 10mg
- MT-8554 1mg
- MT-8554 5mg
- mt8554
- MT8554
- CAS registry numbers
- 1400699-64-0
- ChEMBL ID
- CHEMBL3682589
- InChIKey
- CWEFDWIKLABKBX-UHFFFAOYSA-N
- PubChem compound IDs
- 66548125
- FDA ingredient codes (UNII)
- KIB8V5UR7D
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- elismetrep
- Type
- Synthetic organic
- Drug name stem
- -metrep; -trep
- Action
- Antagonist
- Action type
- Antagonist
- Target
- TRPM8
- Gene symbol
- TRPM8
- Protein identifier
- Q7Z2W7
- Median affinity
- 9.05
- Affinity units
- pIC50
- Mechanism
- Transient receptor potential cation channel subfamily M member 8 inhibitor
- Action type
- Inhibitor
- Target
- Transient receptor potential cation channel subfamily M member 8
- Protein identifier
- Q7Z2W7
Open Targets mechanisms
- Mechanism
- Transient receptor potential cation channel subfamily M member 8 inhibitor
- Action type
- Inhibitor
- Target
- Transient receptor potential cation channel subfamily M member 8
- Condition
- Diabetic Neuropathies
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000783
- Subject identifier
- D003929
- Condition
- Hot Flashes
- Highest recorded phase
- 2
- Condition identifier
- HP:0031217
- Subject identifier
- D019584
- Condition identifier
- EFO_1000783
- Highest recorded phase
- 2
- Condition identifier
- HP_0031217
- Condition identifier
- HP_0031217
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 2
- NCT03172598
- NCT05123196
- NCT03291067
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 1
- Polar surface area
- 96.8
- Calculated partition coefficient (ALogP)
- 6.1
- Calculated partition coefficient (XLogP)
- 6.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 8
- Heavy atoms
- 38
- Molecular formula
- C27H21F3N2O5S
- Monoisotopic mass
- 542.11232743
- Natural product
- No
- Recorded assays
- 1
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (13)
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects
- A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
- Definitive QT Study With MT-8554
- Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy
- Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms
- Mass Balance Study With MT-8554
- MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
- Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy
In development for (1)
- Diabetic neuropathy Phase 2
Targets (1)
- TRPM8 Transient receptor potential cation channel subfamily M member 8 inhibitor